A Virtual Reality Exposure Therapy Application for Iraq War Post Traumatic Stress Disorder

  • Authors:
  • Jarrell Pair;Brian Allen;Matthieu Dautricourt;Anton Treskunov;Matt Liewer;Ken Graap;Greg Reger

  • Affiliations:
  • University of Southern California;University of Southern California;University of Southern California;University of Southern California;University of Southern Californi;Virtually Better, Inc., 2450 Lawrenceville Hwy., Suite 101, Decatur, GA.;United States Army, 98th MED DET (CSC), Tallil AB, LSA Adder, Iraq

  • Venue:
  • VR '06 Proceedings of the IEEE conference on Virtual Reality
  • Year:
  • 2006

Quantified Score

Hi-index 0.00

Visualization

Abstract

Post Traumatic Stress Disorder (PTSD) is reported to be caused by traumatic events that are outside the range of usual human experiences including (but not limited to) military combat, violent personal assault, being kidnapped or taken hostage and terrorist attacks. Initial data suggests that 1 out of 6 Iraq War veterans are exhibiting symptoms of depression, anxiety and PTSD. Virtual Reality (VR) exposure treatment has been used in previous treatments of PTSD patients with reports of positive outcomes. The aim of the current paper is to present the rationale, technical specifications, application features and user-centered design process for the development of a Virtual Iraq PTSD VR therapy application. The VR treatment environment is being created via the recycling of virtual graphic assets that were initially built for the U.S. Army-funded combat tactical simulation scenario and commercially successful X-Box game, Full Spectrum Warrior, in addition to other available and newly created assets. Thus far we have created a series of customizable virtual scenarios designed to represent relevant contexts for exposure therapy to be conducted in VR, including a city and desert road convoy environment. User-Centered tests with the application are currently underway at the Naval Medical Center-San Diego and within an Army Combat Stress Control Team in Iraq with clinical trials scheduled to commence in February 2006.